BR112015008155A2 - combinações - Google Patents
combinaçõesInfo
- Publication number
- BR112015008155A2 BR112015008155A2 BR112015008155A BR112015008155A BR112015008155A2 BR 112015008155 A2 BR112015008155 A2 BR 112015008155A2 BR 112015008155 A BR112015008155 A BR 112015008155A BR 112015008155 A BR112015008155 A BR 112015008155A BR 112015008155 A2 BR112015008155 A2 BR 112015008155A2
- Authority
- BR
- Brazil
- Prior art keywords
- amino
- human
- pharmaceutically acceptable
- acceptable salt
- combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261712869P | 2012-10-12 | 2012-10-12 | |
| US201361833561P | 2013-06-11 | 2013-06-11 | |
| PCT/US2013/064260 WO2014059095A1 (en) | 2012-10-12 | 2013-10-10 | Combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015008155A2 true BR112015008155A2 (pt) | 2017-07-04 |
Family
ID=50477878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015008155A BR112015008155A2 (pt) | 2012-10-12 | 2013-10-10 | combinações |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160263116A1 (https=) |
| EP (1) | EP2906215A4 (https=) |
| JP (1) | JP2015533165A (https=) |
| KR (1) | KR20150067323A (https=) |
| CN (1) | CN104755079A (https=) |
| AU (1) | AU2013329199A1 (https=) |
| BR (1) | BR112015008155A2 (https=) |
| CA (1) | CA2888094A1 (https=) |
| IN (1) | IN2015DN02667A (https=) |
| RU (1) | RU2015117483A (https=) |
| WO (1) | WO2014059095A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2779975T3 (es) | 2014-02-07 | 2020-08-21 | Verastem Inc | Métodos y composiciones para tratar el crecimiento celular anormal |
| GB201510628D0 (en) * | 2015-06-17 | 2015-07-29 | Glaxosmithkline Ip No 2 Ltd | Novel use |
| WO2021047783A1 (en) | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
| US20230201179A1 (en) * | 2020-04-08 | 2023-06-29 | Aptabio Therapeutics Inc. | Agent for treating contrast-induced acute kidney injury |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012005758A (es) * | 2009-11-17 | 2012-06-19 | Glaxosmithkline Llc | Combinacion. |
| WO2012045194A1 (en) * | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Benzodiazepinones as fak inhibitors for treatment of cancer |
| MX2013008654A (es) * | 2011-01-26 | 2013-09-02 | Glaxosmithkline Intellectual Property Ltd | Combinaciones. |
-
2013
- 2013-10-10 KR KR1020157011950A patent/KR20150067323A/ko not_active Withdrawn
- 2013-10-10 WO PCT/US2013/064260 patent/WO2014059095A1/en not_active Ceased
- 2013-10-10 JP JP2015536880A patent/JP2015533165A/ja active Pending
- 2013-10-10 EP EP13845429.3A patent/EP2906215A4/en not_active Withdrawn
- 2013-10-10 US US14/680,416 patent/US20160263116A1/en not_active Abandoned
- 2013-10-10 CN CN201380055435.XA patent/CN104755079A/zh active Pending
- 2013-10-10 RU RU2015117483A patent/RU2015117483A/ru not_active Application Discontinuation
- 2013-10-10 IN IN2667DEN2015 patent/IN2015DN02667A/en unknown
- 2013-10-10 CA CA2888094A patent/CA2888094A1/en not_active Abandoned
- 2013-10-10 AU AU2013329199A patent/AU2013329199A1/en not_active Abandoned
- 2013-10-10 BR BR112015008155A patent/BR112015008155A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20160263116A1 (en) | 2016-09-15 |
| RU2015117483A (ru) | 2016-12-10 |
| CN104755079A (zh) | 2015-07-01 |
| EP2906215A4 (en) | 2016-05-18 |
| AU2013329199A1 (en) | 2015-04-16 |
| EP2906215A1 (en) | 2015-08-19 |
| CA2888094A1 (en) | 2014-04-17 |
| JP2015533165A (ja) | 2015-11-19 |
| WO2014059095A1 (en) | 2014-04-17 |
| IN2015DN02667A (https=) | 2015-09-04 |
| KR20150067323A (ko) | 2015-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2017000105A (es) | Métodos y productos de fármaco para tratar enfermedad de alzheimer | |
| EA201491299A1 (ru) | Карбаматные соединения, их получение и применение | |
| BR112015008155A2 (pt) | combinações | |
| BR112015007778A2 (pt) | profármacos neutralizantes de vegf para o tratamento de condições oculares | |
| BR112015000150A2 (pt) | composições farmacêuticas dissuasoras de abuso de liberação controlada | |
| CL2014002077A1 (es) | Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple. | |
| EA201500365A1 (ru) | Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака | |
| CL2012002192A1 (es) | Sal de metilnaltrexona cuyo anión es un excipiente anfifílico; composición farmacéutica para administración oral que comprende esta sal y un excipiente anfifílico; método de preparación de la composición farmaceutica; método para reducir efectos secundarios de la terapia opioide; producto; y paquete multidía. | |
| HK1223304A1 (zh) | 包含二甲双胍和二氢槲皮素的药物组合及其用於治疗癌症的用途 | |
| MX2015002005A (es) | Combinacion de inhibidor de p13k e inhibidor de c-met. | |
| BR112012024887A2 (pt) | grânulos de quitosana, preenchedor, processo para preparar os grânulos de quitosana, kit e disposto de injeção | |
| BR112013017722A2 (pt) | combinação | |
| MD20150057A2 (ro) | Compoziţie farmaceutică cu conţinut de hidroclorură de nalbufină, utilizarea ei pentru tratamentul sindromului algic de intensitate medie şi înaltă şi metodă de obţinere a compoziţiei farmaceutice | |
| PH12015500653B1 (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof | |
| EA201390345A1 (ru) | Терапевтическое болеутоляющее средство | |
| BR102012028120B8 (pt) | Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento | |
| BR112013019775A2 (pt) | composto, composição farmacêutica e método para tratar declínio cognitivo ou doença de alzheimer em um paciente | |
| BR112013018296A2 (pt) | tratamento de disfunções cognitivas em esquizofrenia | |
| BR112012030485A2 (pt) | composição para prevenção ou tratamento de osteoporose e processo de fabricação para a mesma | |
| ES2469240B1 (es) | Uso de un agente fotosensible capaz de producir especies reactivas de oxígeno en la preparación de un medicamento útil para la terapia fotodinámica de una enfermedad relacionada con células madre, uso "in vitro" y composición farmacéutica. | |
| EA201270445A1 (ru) | Комбинация | |
| MX2013013574A (es) | Composicion farmaceutica que comprende drotaverina. | |
| BR112016015175A2 (pt) | Formulação farmacêutica, método para a fabricação de uma formulação farmacêutica compreendendo sildenafila e clomipramina e comprimido | |
| EA201500882A1 (ru) | Комбинация | |
| BR112015005392A2 (pt) | formulação de comprimido de um inibidor de fosfatidilinositol 3-cinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |